Navigation Links
Lymphoma in Biological Technology

The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research

... N.Y., July 6 /PRNewswire/ -- The Leukemia & lymphoma Society (LLS) and The International Waldenstrom's ... About The Leukemia & lymphoma Society The Leukemia & lymphoma Society(R) (LLS) is the world's largest voluntary ...

Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma

... ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 ... for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a). The study, which is being ... Officer of Yaupon. Cutaneous T-cell lymphoma is a cancer of the T-lymphocytes in the skin. ...

Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients

... other investigational uses, there was one case of lymphoma among 2,657 CIMZIA-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In CIMZIA ... and open label) a total of three cases of lymphoma were observed among 2,367 patients. This is ...

Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting

... p.m. ET Track: Developmental Therapeutics, lymphoma and Plasma Cell Disorders Session: New ... 2009 from 2:00 p.m. to 6:00 p.m. ET Track: lymphoma and Plasma Cell Disorders Session: lymphoma and Plasma Cell Disorders Location: Level ...

Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting

... drugs for the treatment of non-Hodgkin's lymphoma (NHL), and a preclinical study evaluating the ... with previously treated CLL or small lymphocytic lymphoma (SLL). Abstract 8571 (May 30, 2009): ... Therapeutic Drugs in Models of Non-Hodgkin's lymphoma In addition, Trubion will also present at the ...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

... in patients with relapsed non-Hodgkin's lymphoma and a poster presentation of the first interim ... phase 1 clinical study in relapsed non-Hodgkin's lymphoma patients. These data were published in the ... 2 clinical trial in patients with non-Hodgkin's lymphoma with blinatumomab. In addition, by mid-2009, we ...

Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million

... pixantrone for relapsed aggressive non-Hodgkin's lymphoma (NHL) and OPAXIO for non-small cell lung and ... for more information. About Non-Hodgkin's lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of ...

FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review

... for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. ... option for follicular B-cell non-Hodgkin's lymphoma patients," said James A. Bianco, M.D., CEO of ... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ...

Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug

... with follicular NHL. Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation ... for more information. About Non-Hodgkin's lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation ...

High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma

... majority of high risk or relapsed non-Hodgkin's lymphoma patients." High-dose Zevalin was well tolerated ... low-grade or follicular B-cell non- Hodgkin's lymphoma (NHL), including patients with rituximab ... About Non-Hodgkin's Lymphoma Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation ...

Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy

... on the treatment of follicular non-Hodgkin's lymphoma and we would expect it to significantly enhance ... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ... with CD20-positive follicular non-Hodgkin's lymphoma who had achieved a partial response or a complete ...

FDA Meeting Provides Green Light for Cell Therapeutics Submission of Supplemental Filing for Zevalin(R) Label Expansion

... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ... underutilized in the treatment of non-Hodgkin's lymphoma patients, especially among community ... treatment option for patients with follicular lymphoma and I would look forward to the FDA's approving ...

CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application

... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ... as first-line consolidation therapy in follicular lymphoma patients, was sponsored by Bayer Schering Pharma ... Zevalin in patients with CD20-positive follicular lymphoma who had achieved a partial remission or a ...

The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia

... Provid Pharmaceuticals, Inc. and The Leukemia & lymphoma Society (LLS) today jointly announced ... . About The Leukemia & lymphoma Society The Leukemia & lymphoma Society(R), headquartered in White Plains, ...

Proteolix's Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma

... (WM) is a slow-growing type of non-Hodgkin's lymphoma that starts in white blood cells called B lymphocytes. WM is also called lymphoplasmacytic lymphoma because it occurs when abnormal lymphoplasmacytic ... its safety and efficacy in multiple myeloma, lymphoma and solid tumor malignancies. Proteolix is also ...

Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results

... complete and partial responses in late stage lymphoma patients. The BiTE antibody could also clear the ... responses in patients with mantle cell lymphoma (MCL) -- a disease that is difficult to treat. ... activity for MT103 in late-stage non-Hodgkin's lymphoma patients and completing preclinical development ...

BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update

... pivotal trial in patients with cutaneous t-cell lymphoma In October, BioCryst began enrolling patients ... candidate, forodesine HCl for cutaneous t-cell lymphoma (CTCL). As presented at the 2007 American ... trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase ...

Millennium Over-Delivers on 2007 Goals and Financial Guidance

... Company- sponsored Phase III non-Hodgkin's lymphoma (NHL) trial. The trial is evaluating VELCADE ... for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. ... with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In ...

Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results

... -- Prepare for further expansion in non-Hodgkin's lymphoma through completion of patient enrollment in ... for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. ... with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In ...

REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide

... common. Reports of a type of blood cancer called lymphoma in patients on REMICADE or other TNF blockers are ... a rare type of lymphoma, hepatosplenic T cell lymphoma (HSTL), that often results in death. If you take ... or other TNF blockers, your risk for developing lymphoma or other cancers may increase. You should also ...

Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales

... in front-line MM and Non-Hodgkin's lymphoma (NHL). Clinical Pipeline Highlights In addition ... for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. ... with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In ...

Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference

... (RFC-1), in Patients with Relapsed or Refractory lymphoma Reveals Marked Activity in T-Cell Malignancies" ... with relapsed or refractory non- Hodgkin's lymphoma (NHL) and Hodgkin's disease. Responses were ... non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate ...

Genmab Amends HuMax-CD4 Pivotal Study in CTCL

... Receives Orphan Drug Designation for Nodal T-Cell lymphoma Summary: Genmab Announced Today it has Amended ... and for the treatment of refractory nodal T-cell lymphoma in Europe. HuMax-CD4 previously received Fast ... "The potential of HuMax-CD4 in treating T-cell lymphoma patients with unmet medical needs continues to ...

Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma

... Drug Designation for the Treatment of Hodgkin's lymphoma in the United States - BOULDER, Colo. and ... trial in relapsed and refractory Hodgkin's lymphoma were presented at the American Society of ... in hematological malignancies. About Hodgkin's lymphoma ...

Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial

... pixantrone in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) for whom anthracycline-related drugs are typically not to be used ... for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). CTI expects to complete the submission this quarter and will ...

Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting

... immunotherapeutic with potent in vitro activity against B-cell lymphoma B-cell depletion with agents such as Rituxan(R) has proven successful ... was identified that demonstrated highly potent activities against B-cell lymphoma cells in vitro . The CD79BxDR SCORPION can bind to two different ...

BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update

... Phase 2 pivotal study of Forodesine HCl in patients with cutaneous T-cell lymphoma (CTCL), and has enrolled more than half of the targeted patients. The ... successful, that the pivotal trial with Forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization ...

New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease

... for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 CIMZIA(R)-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. The potential role of TNF blocker ...

Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting

... to study its compounds initially in rheumatoid arthritis and non-Hodgkin's lymphoma and eventually intends to explore their potential in other inflammatory ... Syk is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin's lymphoma Cell Lines without Concomitant Inhibition of JAK" (abstract # 1794) ...

Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008

... induction in previously untreated patients with follicular non-Hodgkin's lymphoma based on First-line Indolent Trial data. -- Announced that CTI has ... (BBR2778) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL) and anticipates reporting top-line results in November. -- ...

Rigel Announces Third Quarter 2008 Financial Results and Clinical Update

... for T-cell lymphoma within the next several months. The ongoing Phase 2 lymphoma clinical trial is continuing and is focused on diffuse large B-cell, ... lymphomas, including chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL). Rigel plans to present further results from this ongoing ...

BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update

... 6-9, 2008. -- The forodesine HCl pivotal trial in cutaneous T-cell lymphoma (CTCL) continues to enroll subjects with CTCL stages IIB through IVA ... successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization ...

Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results

... response rate in 28 patients with multiply recurrent non-Hodgkin's lymphoma (NHL) who were treated with motexafin gadolinium (MGd, Xcytrin(R)) ... oral Btk inhibitor, PCI-32765, in patients with recurrent B-cell lymphoma in the fourth quarter of calendar 2008. This study is designed to ...

Genzyme Files Applications for Approval of Mozobil in the United States and Europe

... for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma. The company has requested priority review of its ... confirmed the potential of Mozobil to effectively and predictably prepare lymphoma and multiple myeloma patients for an autologous transplant. Both studies ...

Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma

... -- At the 10th International Conference on Malignant lymphoma in Lugano, Switzerland data were presented from a phase I/II ... using this combination in patients with follicular or diffuse large B-cell lymphoma are warranted." About the Study Of the 30 patients enrolled on this ...

BioCryst Reports First Quarter 2008 Financial Results and Clinical Update

... Recent Corporate Highlights Forodesine HCl cutaneous T-cell lymphoma (CTCL) trial update and chronic lymphocytic leukemia (CLL) trial ... successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for ...

Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales

... VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated ... period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety ...

Genmab Announces Year End 2007 Financial Results

... lymphoma, 2 RA Phase III studies, Phase II relapsed diffuse large B-cell lymphoma study HuMax-CD38 Phase I/II multiple myeloma study Achieved positive ... HuMax-CD20 Phase II RA data Final HuMax-CD4 Phase II cutaneous T-cell lymphoma (CTCL) data R1507 Phase I sarcoma data Presented pre-clinical data: ...

Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008

... with Zevalin over rituximab for relapsed or refractory follicular lymphoma patients following initial therapy and that such results will help grow ... pixantrone phase III clinical trial in aggressive, relapsed non-Hodgkin's lymphoma (NHL), known as the EXTEND or PIX301 trial, are expected in the summer of ...

CuraGen Reports Fourth Quarter and Year End 2007 Financial Results

... of cancer: -- Updated Phase II results for the treatment of T-cell lymphoma during the second quarter of 2008; -- Updated Phase II results of ... trial of intravenous belinostat for the treatment of peripheral T-cell lymphoma by the fourth quarter of 2008. CR011-vcMMAE, antibody-drug conjugate for ...
Other Contents
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
Other TagsOther Tags